[Bony lesion with prostate cancer].

Area of Science:

• Oncology
• Bone Biology
• Metastasis Research

Background:

• Bone metastasis is a significant complication of prostate cancer, contributing to morbidity and mortality.
• Osteolysis, or bone breakdown, is a hallmark of prostate cancer bone metastasis, driven by osteoclast overactivity.
• Understanding the molecular mechanisms of osteolysis is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To review the current understanding of the mechanisms underlying prostate cancer bone metastasis and osteolysis.
• To summarize the therapeutic approaches targeting bone metabolism in prostate cancer patients with bone metastasis.
• To highlight key factors involved in tumor-induced osteoclast activation as potential therapeutic targets.

Main Methods:

• Review of current literature on prostate cancer bone metastasis.
• Analysis of factors promoting osteolysis, including Receptor Activator of Nuclear factor-kappa B ligand (RANKL) and Matrix Metalloproteinases (MMPs).
• Summary of therapeutic agents targeting osteoclasts and their role in standard management.

Main Results:

• Prostate cancer bone metastases activate osteoclasts, leading to significant bone degradation.
• Key factors such as RANKL and MMPs secreted by prostate cancer cells drive osteolysis.
• Targeted therapies including zoledronic acid, anti-RANKL antibodies, cathepsin K inhibitors, and anti-PTHrP antibodies are integral to current management.

Conclusions:

• Management of bone metabolism is critical in prostate cancer bone metastasis.
• Factors promoting osteolysis represent viable therapeutic targets.
• Targeted osteoclast-focused agents, combined with chemotherapy and hormone therapy, form the standard of care.